Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan-Dec:25:1076029619834350.
doi: 10.1177/1076029619834350.

Impact of Antithrombin Supplementation and Concomitant Anticoagulation Therapy in Pediatric Patients With Disseminated Intravascular Coagulation

Hiroyuki Nagafuchi  1 , Yutaka Eguchi  2 , Toshiaki Ikeda  3
Affiliations

Impact of Antithrombin Supplementation and Concomitant Anticoagulation Therapy in Pediatric Patients With Disseminated Intravascular Coagulation

Hiroyuki Nagafuchi et al. Clin Appl Thromb Hemost. 2019 Jan-Dec.

Abstract

We aimed to evaluate the efficacy and safety of antithrombin (AT) supplementation and concomitant anticoagulation therapy in 65 children who met the Japanese Ministry of Health and Welfare (JMHW) disseminated intravascular coagulation (DIC) criteria and had received AT concentrate and/or other concomitant anticoagulants. The primary efficacy end point was to determine standardized mortality ratio (SMR). The secondary efficacy end points were DIC resolution rate and pediatric sequential organ failure assessment (pSOFA) score on day 3. The 28-day mortality rate was 6.8%; SMR was 0.55. Disseminated intravascular coagulation resolution rate on day 3 was 54.5%. The JMHW DIC scores at day 0 ( P = .005) and pSOFA scores at day 3 ( P = .018) were significantly lower in patients with resolution of DIC than in those without resolution of DIC. The target cutoff value for JMHW DIC score on day 0 was 6. No bleeding-related adverse events were associated with AT administration. In children with DIC, AT supplementation and concomitant anticoagulation therapy can be safely used as initial treatment when JMHW DIC score is 6; it may improve DIC resolution, organ failure, and mortality rates.

Keywords: JAAM DIC criteria; JMHW DIC criteria; antithrombin; children; disseminated intravascular coagulation.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declare no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flowchart of patients. AT indicates antithrombin; NM, nafamostat mesylate; rhTM, recombinant human thrombomodulin.
Figure 2.
Figure 2.
Correlation between Japanese Ministry of Health and Welfare (JMHW) disseminated intravascular coagulation (DIC) score and Japanese Association for Acute Medicine (JAAM) DIC score. Both JMHW DIC and JAAM DIC scores on day 0 (open circle) and day 3 (closed circle) were plotted for 44 patients.
See this image and copyright information in PMC

References

    1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341(8):586–592. - PubMed
    1. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35(9):2191–2195. - PubMed
    1. Gando S, Saitoh D, Ogura H, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med. 2008;36(1):145–150. - PubMed
    1. Wada H, Wakita Y, Nakase T, et al. Outcome prediction of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost. 1995;74(3):848–852. - PubMed
    1. Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34(3):625–631. - PubMed

LinkOut - more resources